Cyclophosphamide-refractory scleroderma-associated interstitial lung disease: Remarkable clinical and radiological response to a single course of rituximab combined with high-dose corticosteroids

Therapeutic Advances in Respiratory Disease

Volumn 5, Issue 5, 2011, Pages 299-304

  Haroon, Muhammad ^a   McLaughlin, Patrick ^a   Henry, Michael ^a   Harney, Sinead ^a  

^a University College Cork and INFANT Centre   (Ireland)

Author keywords

cyclophosphamide; interstitial lung disease; rituximab; scleroderma

Indexed keywords

ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; CENTROMERE ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; RHEUMATOID FACTOR; RITUXIMAB;

ADULT; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DETERIORATION; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DYSPNEA; EDEMA; ERYTHROCYTE SEDIMENTATION RATE; ESOPHAGUS MOTILITY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; MALE; ORGANIZING PNEUMONIA; POLYARTHRITIS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SCLERODERMA; SHORT COURSE THERAPY; THORAX RADIOGRAPHY; TREATMENT RESPONSE; WALKING;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; LUNG DISEASES, INTERSTITIAL; MALE; PULSE THERAPY, DRUG; SCLERODERMA, LIMITED; TREATMENT OUTCOME;

EID: 80052640206     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465811407786     Document Type: Article

References (32)

1. Biogen Idec and Genentech (2010) Rituxan [package insert] Biogen Idec Inc. and Genentech USA, Inc. February 2010: South San Francisco, CA.
2. Bosello S. De Santis M. Lama G. Spanò C. Angelucci C. Tolusso B. (2010) B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 12: R54–R54.
3. Bosello S. De Santis M. Lama G. (2007) Clinical improvement in systemic sclerosis patients treated with anti-CD20. Arthritis Rheum Suppl 56: S494's494.
4. Bouros D. Wells A.U. Nicholson A.G. Colby T.V. Polychronopoulos V. Pantelidis P. (2002) Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165: 1581–1586.
5. Calabrese L.H. Molloy E.S. (2008) Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis 67(Suppl. 3): iii64–iii65.
6. Daoussis D. Liossis S.N. Tsamandas A.C. Kalogeropoulou C. Kazantzi A. Sirinian C. (2010a) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 49: 271–280.
7. Daoussis D. Liossis S.N. Tsamandas A.C. Kalogeropoulou C. Kazantzi A. Korfiatis P. (2010b) Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin Arthritis Rheum 40: 127–136.
8. El Fassi D. Nielsen C.H. Junker P. Hasselbalch H.C. Hegedüs L. (2010) Systemic adverse events following rituximab therapy in patients with Graves’ disease. J Endocrinol Invest 2010 Epub ahead of print.
9. Famularo G. Giacomelli R. Alesse E. Cifone M.G. Morrone S. Boirivant M. (1989) Polyclonal B lymphocyte activation in progressive systemic sclerosis. J Clin Lab Immunol 29: 59–63.
10. FDA (2007) Rituxan warning. FDA Consum 41: 3–3.
11. Fischer A. Meehan R.T. Feghali-Bostwick C.A. West S.G. Brown K.K. (2006) Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest 130: 976–981.
12. Fischer A. Swigris J.J. Groshong S.D. Cool C.D. Sahin H. Lynch D.A. (2008) Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest 134: 601–605.
13. Kim D.S. Yoo B. Lee J.S. Kim E.K. Lim C.M. Lee S.D. (2002) The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 19: 121–127.
14. Kraaij M.D. van Laar J.M. (2008) The role of B cells in systemic sclerosis. Biologics 2: 389–395.
15. Kranick S.M. Mowry E.M. Rosenfeld M.R. (2007) Progressive multifocal leukoencephalopathy after rituximab in a case of non-Hodgkin lymphoma. Neurology 69: 704–706.
16. Lafyatis R. Kissin E. York M. Farina G. Viger K. Fritzler M.J. (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60: 578–583.
17. Lombardi S. Quartuccio L. Franzolini N. (2008) Rituximab for the long term treatment of severe cutaneous involvement in systemic sclerosis. Arthritis Rheum Suppl 58: S822's823.
18. Lomeo R.M. Cornella R.J. Schabel S.I. Silver R.M. (1989) Progressive systemic sclerosis sine scleroderma presenting as pulmonary interstitial fibrosis. Am J Med 87: 525–527.
19. McGonagle D. Tan A.L. Madden J. Rawstron A.C. Rehman A. Emery P. (2008) Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford) 47: 552–553.
20. Nadashkevich O. Davis P. Fritzler M.J. (2004) A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit 10: CR615–CR621.
21. Park J.H. Kim D.S. Park I.N. Jang S.J. Kitaichi M. Nicholson A.G. (2007) Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 175: 705–711.
22. Saito E. Fujimoto M. Hasegawa M. Komura K. Hamaguchi Y. Kaburagi Y. (2002) CD19-dependent B lymphocyte signalling thresholds influence skin fibrosis and autoimmunity in the tightskin mouse. J Clin Invest 109: 1453–1462.
23. Sato S. Fujimoto M. Hasegawa M. Takehara K. (2004) Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 50: 1918–1927.
24. Sato S. Hasegawa M. Fujimoto M. Tedder T.F. Takehara K. (2000) Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 165: 6635–6643.
25. Smith V. Van Praet J.T. Vandooren B. Van der Cruyssen B. Naeyaert J.M. Decuman S. (2010) Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 69: 193–197.
26. Steen V.D. Medsger T.A. (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66: 940–944.
27. Tashkin D.P. Elashoff R. Clements P.J. Roth M.D. Furst D.E. Silver R.M. (2007) Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176(10): 1026–1034.
28. Trang G. Steele R. Baron M. Hudson M. (2010) Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatol Int 2010 Epub ahead of print.
29. Whitfield M.L. Finlay D.R. Murray J.I. Troyanskaya O.G. Chi J.T. Pergamenschikov A. (2003) Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 100: 12319–12324.
30. Wolach O. Bairey O. Lahav M. (2010) Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 89: 308–318.
31. Wollheim F.A. (2004) Is rituximab a potential new therapy in systemic sclerosis? New evidence indicates the presence of CD20-positive B-lymphocytes in scleroderma skin. J Clin Rheumatol 10: 155–155.
32. Yoo W.H. (2010) Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab. Rheumatol Int 2010 Epub ahead of print.